Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults
Fundamental & Clinical Pharmacology · 2026-07 · 40 (4)
DOI: 10.1111/fcp.70108 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 17.07.2026. Verfasst von Kimberly Shudofsky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, VieCuri Medical Center, Venlo, the Netherlands. Hauptthemen laut MEDLINE: Midazolam, Acute Kidney Injury, Renal Insufficiency, Chronic, Hypnotics and Sedatives. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Midazolam (MDZ) is used for sedation in critically ill patients. Although previous studies have examined MDZ pharmacokinetics in ICU patients, the differential effects of acute kidney injury (AKI) and chronic kidney disease (CKD), particularly in cohorts including COVID‐19 and non‐COVID‐19 patients, remain insufficiently characterised.
Objectives
To investigate whether AKI and CKD are associated with dose‐normalised exposure of MDZ, 1‐hydroxy‐midazolam (1‐OH‐MDZ) and 1‐hydroxy‐midazolam glucuronide (1‐OH‐MDZ‐G) in critically ill adults.
Methods
In this retrospective observational study, ICU patients receiving continuous intravenous MDZ were included. Plasma concentrations of MDZ, 1‐OH‐MDZ and 1‐OH‐MDZ‐G were converted to concentration‐to‐dose (C/D) ratios. Cross‐sectional analysis used the first sample per patient; longitudinal analysis included all samples in GEE models. Analyses were adjusted for age, sex, BMI, COVID‐19 status, CYP3A4 inhibitor use, APACHE IV score, time since MDZ initiation and CRP.
Results
Forty‐seven patients contributed 137 samples. In the cross‐sectional analysis, C/D ratios of MDZ and 1‐OH‐MDZ did not differ between patients with and without AKI, whereas 1‐OH‐MDZ‐G C/D ratios were higher in AKI (median [IQR] 14.54 [6.14–26.20] vs. 4.53 [2.52–6.00]; p < 0.01). Longitudinal analysis showed that AKI ( β = 0.87), AKI Stage 1 ( β = 0.81), AKI Stages 2–3 ( β = 0.97) and CKD ( β = 0.72) were all significantly associated with higher 1‐OH‐MDZ‐G C/D ratios (all p ≤ 0.03). No significant associations were observed for MDZ or 1‐OH‐MDZ.
Conclusion
AKI and CKD are associated with accumulation of 1‐OH‐MDZ‐G in critically ill patients. Monitoring 1‐OH‐MDZ‐G may help identify patients at risk of prolonged sedation and adverse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, VieCuri Medical Center, Venlo, the Netherlands.
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
- Department of Clinical Pharmacy, Flevo Hospital, Almere, the Netherlands.
- Department of Clinical Pharmacy, CARIM, the Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
- Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.
ORCID-Profile: Kimberly Shudofsky
Zitieren
APA
Shudofsky, K., Abma, J., Driessen, J., Slikkerveer, M., Vanmolkot, F., Janssen, P., & le Noble, J. (2026). Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults. Fundamental & Clinical Pharmacology, 40(4). https://doi.org/10.1111/fcp.70108
Vancouver
Shudofsky K, Abma J, Driessen J, Slikkerveer M, Vanmolkot F, Janssen P, et al. Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults. Fundamental & Clinical Pharmacology. 2026;40(4). doi:10.1111/fcp.70108
BibTeX
@article{Shudofsky2026,
author = {Shudofsky, Kimberly and Abma, Johanna and Driessen, Johanna and Slikkerveer, Marielle and Vanmolkot, Floris and Janssen, Paddy and le Noble, Jos},
title = {Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration‐To‐Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
volume = {40},
number = {4},
doi = {10.1111/fcp.70108}
}
EUVIMED